Yasuhiro Shimizu

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi et al. · The Lancet · 2016 · 1.1K citations

Surgical Oncology, Oncology, Pancreatic Cancer +6

Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer

Tomoki Ebata, Satoshi Hirano, Masaru Konishi et al. · British journal of surgery · 2018 · 378 citations

Pancreatic Ductal Adenocarcinoma Derived From IPMN and Pancreatic Ductal Adenocarcinoma Concomitant With IPMN

Koji Yamaguchi, Shuichi Kanemitsu, Takashi Hatori et al. · Pancreas · 2011 · 269 citations

Multicenter study of early pancreatic cancer in Japan

Atsushi Kanno, Atsushi Masamune, Keiji Hanada et al. · Pancreatology · 2017 · 262 citations

Pancreatic Cancer, Pancreatic Fluid Collection, Medicine +5

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Kohei Nakachi, Masafumi Ikeda, Masaru Konishi et al. · The Lancet · 2023 · 214 citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +9